Overview

The Repatriation Medical Authority Instrument No. 38 of 2011 amends the Statement of Principles concerning malignant neoplasm of the brain, under the Veterans' Entitlements Act 1986. This legislative instrument was enacted to address specific concerns regarding the existing criteria for veterans' entitlements, particularly focusing on the factors that contribute to the development of malignant brain neoplasms. The Authority, under its legislative mandate, sought to refine the criteria by replacing and restructuring existing factors, thereby ensuring more accurate and relevant assessments of veterans' claims. This Instrument was finalised after a thorough investigation process, which included public notices and submissions from relevant stakeholders, aiming to uphold the policy objective of providing just compensation and support to veterans affected by such conditions. The legislative instrument was determined by the Repatriation Medical Authority in accordance with the legislative framework provided by the Veterans' Entitlements Act 1986 and the Legislative Instruments Act 2003. This process underscores the commitment to evidence-based and inclusive decision-making, ensuring that the amendments reflect the latest medical understanding and the needs of the veteran community. The Authority's actions in this regard are designed to maintain the integrity and effectiveness of the veterans' compensation system, addressing identified gaps and enhancing the fairness of entitlements for those who have served.

Scope and Application

This legislation, the Repatriation Medical Authority Instrument No. 38 of 2011, pertains to amendments of the Veterans' Entitlements Act 1986 and the Military Rehabilitation and Compensation Act 2004, specifically addressing the Statement of Principles Instrument concerning malignant neoplasm of the brain. The instrument applies to veterans, service personnel, and their dependants, and it pertains to the medical condition of malignant neoplasm of the brain, adjusting the factors that determine eligibility for benefits under the Acts. The amendments include changes to the criteria for ionising radiation and the removal of certain definitions that are now encompassed within the new criteria. The instrument was determined by the Repatriation Medical Authority after an investigation, which involved advertising in the Government Notices Gazettes and soliciting submissions from relevant parties, including the Repatriation Commission and organisations representing veterans and service personnel. The instrument's effect is governed by the Legislative Instruments Act 2003, and it includes a specified date of effect to ensure the timely application of the changes. The Authority is available to provide a list of references related to the condition for any person or organisation as specified in the Veterans' Entitlements Act 1986, upon written request to the Repatriation Medical Authority in Brisbane.

Key Provisions

The key operative sections of this instrument pertain to the amendment of the Statement of Principles concerning malignant neoplasm of the brain, which is outlined in Statement of Principles Instrument No. 59 of 2008. Specifically, section 2 of the instrument replaces existing factor 6(a) with a new factor concerning "ionising radiation" (section 2(1)). It also deletes existing factor 6(b) as it is now subsumed by the new factor 6(a) (section 2(2)). Additionally, the instrument re-numbers existing factor 6(c) as 6(b) (section 2(3)), revises clause 7 to reflect these changes (section 2(4)), updates the definition of "cumulative equivalent dose" in clause 9 (section 2(5)), and deletes the definitions of "a course of therapeutic radiation" and "atomic radiation" from clause 9 (section 2(6)). This instrument is determined under subsection 196B(3) and (8) of the Veterans' Entitlements Act 1986 (VEA) and specifies a date of effect in accordance with subsection 12(1)(a) of the Legislative Instruments Act 2003 (section 3). The obligations imposed by this instrument on the parties it governs include the requirement for the Repatriation Medical Authority to undertake an investigation into malignant neoplasm of the brain and to advertise its intention to do so in the Government Notices Gazettes (section 4). The Authority must also circulate notices of its intention to investigate to a wide range of organisations representing veterans, service personnel, and their dependants. Furthermore, the Authority is required to invite submissions from the Repatriation Commission, organisations, and persons referred to in section 196E of the VEA, and any person with expertise in the field. The Authority must consider any submissions received during the investigation (section 5). There are no specific offences, penalties, or consequences for breach outlined in the instrument itself. However, any person or organisation referred to in subsection 196E(1)(a) to (c) of the VEA can request a list of references relating to the condition by making a written request to the Repatriation Medical Authority at the specified address (section 6). It is implied that failure to comply with the statutory obligations could lead to legal consequences under the relevant acts, although these are not explicitly stated in the explanatory notes.